Arrowhead Pharmaceuticals - ARWR Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $53.00
  • Forecasted Upside: 128.74%
  • Number of Analysts: 14
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
▲ +1.97 (9.29%)

This chart shows the closing price for ARWR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Arrowhead Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARWR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARWR

Analyst Price Target is $53.00
▲ +128.74% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Arrowhead Pharmaceuticals in the last 3 months. The average price target is $53.00, with a high forecast of $90.00 and a low forecast of $27.00. The average price target represents a 128.74% upside from the last price of $23.17.

This chart shows the closing price for ARWR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 14 polled investment analysts is to moderate buy stock in Arrowhead Pharmaceuticals. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/30/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$50.00Low
11/30/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$40.00 ➝ $37.00Low
9/19/2023CitigroupInitiated CoverageNeutral$33.00Low
8/9/2023HC WainwrightReiterated RatingBuy ➝ Buy$90.00Low
8/8/2023Chardan CapitalReiterated RatingBuy ➝ Buy$60.00Low
8/8/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$60.00Low
8/8/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$79.00 ➝ $47.00Low
7/21/2023TD CowenInitiated CoverageOutperformLow
7/20/2023B. RileyReiterated RatingBuy ➝ Buy$55.00Low
6/30/2023HC WainwrightReiterated RatingBuy ➝ Buy$90.00Low
6/2/2023Piper SandlerBoost Target$52.00 ➝ $59.00Low
5/12/2023SVB LeerinkDowngradeOutperform ➝ Market PerformLow
5/12/2023SVB SecuritiesDowngradeOutperform ➝ Market Perform$40.00Low
5/3/2023500.comReiterated RatingReiteratesLow
4/26/2023Sumitomo Mitsui Financial GroupInitiated CoverageOutperform$80.00Low
4/12/2023SVB LeerinkUpgradeMarket Perform ➝ OutperformLow
4/12/2023SVB SecuritiesUpgradeMarket Perform ➝ Outperform$21.00 ➝ $35.00Low
3/21/2023Sanford C. BernsteinInitiated CoverageMarket Perform$27.00Low
2/10/2023HC WainwrightReiterated RatingBuy$90.00Low
2/10/2023Chardan CapitalReiterated RatingBuy$60.00Low
2/8/2023B. RileyLower TargetBuy$59.00 ➝ $55.00Low
2/7/2023Royal Bank of CanadaLower TargetOutperform$83.00 ➝ $77.00Low
2/7/2023Piper SandlerLower TargetOverweight$55.00 ➝ $52.00Low
2/7/2023Robert W. BairdLower TargetOutperform$60.00 ➝ $58.00Low
1/10/2023Chardan CapitalLower Target$82.00 ➝ $60.00Low
1/9/2023Piper SandlerLower Target$64.00 ➝ $55.00Low
12/6/2022HC WainwrightLower TargetBuy$110.00 ➝ $90.00Low
11/30/2022The Goldman Sachs GroupReiterated RatingBuy$65.00 ➝ $66.00Low
11/30/2022B. RileyLower TargetBuy$65.00 ➝ $59.00Low
11/29/2022Jefferies Financial GroupLower TargetBuy$92.00 ➝ $75.00Low
11/29/2022Morgan StanleyLower TargetEqual Weight$41.00 ➝ $37.00Low
11/29/2022SVB LeerinkLower TargetMarket Perform$33.00 ➝ $31.00Low
11/10/2022SVB LeerinkBoost TargetMarket Perform$32.00 ➝ $33.00Low
11/9/2022Piper SandlerLower TargetOverweight$72.00 ➝ $64.00Low
9/9/2022Morgan StanleyInitiated CoverageEqual Weight$41.00Low
8/8/2022The Goldman Sachs GroupBoost TargetBuy$58.00 ➝ $65.00Low
8/5/2022Chardan CapitalBoost Target$80.00 ➝ $82.00Low
7/14/2022HC WainwrightReiterated RatingBuy$110.00Low
6/3/2022HC WainwrightBoost TargetBuy$100.00 ➝ $110.00High
5/24/2022The Goldman Sachs GroupLower TargetBuy$90.00 ➝ $66.00High
5/11/2022Piper SandlerLower Target$89.00 ➝ $72.00High
5/11/2022Robert W. BairdUpgradeNeutral ➝ Outperform$71.00 ➝ $60.00High
4/1/2022Cantor FitzgeraldReiterated RatingOverweightN/A
3/23/2022HC WainwrightReiterated RatingBuy$100.00High
2/8/2022HC WainwrightReiterated RatingBuy$100.00Low
2/3/2022SVB LeerinkLower TargetMarket Perform$46.00 ➝ $36.00Low
1/28/2022SVB LeerinkBoost TargetMarket Perform$45.00 ➝ $46.00High
1/19/2022The Goldman Sachs GroupUpgradeNeutral ➝ BuyHigh
11/23/2021SVB LeerinkBoost TargetMarket Perform$44.00 ➝ $45.00Low
8/10/2021HC WainwrightBoost TargetBuy$95.00 ➝ $100.00Medium
8/6/2021Chardan CapitalLower TargetBuy$97.00 ➝ $94.00High
7/2/2021HC WainwrightReiterated RatingBuy$95.00N/A
7/2/2021Piper SandlerLower TargetOverweight$109.00 ➝ $89.00High
6/27/2021SVB LeerinkReiterated RatingHoldHigh
6/21/2021Piper SandlerBoost TargetOverweight ➝ Overweight$99.00 ➝ $109.00Low
2/8/2021CitigroupBoost Target$90.00 ➝ $110.00Medium
2/8/2021B. RileyBoost TargetBuy$98.00 ➝ $106.00High
2/5/2021Piper SandlerBoost TargetOverweight$90.00 ➝ $99.00High
2/5/2021Chardan CapitalBoost TargetBuy$81.00 ➝ $97.00High
2/5/2021HC WainwrightBoost TargetBuy$90.00 ➝ $95.00High
12/21/2020Robert W. BairdDowngradeOutperform ➝ Neutral$75.00High
12/15/2020UBS GroupInitiated CoverageBuy$95.00Low
11/24/2020Royal Bank of CanadaBoost TargetPositive ➝ Outperform$62.00 ➝ $80.00High
11/24/2020Cantor FitzgeraldBoost TargetOverweight$58.00 ➝ $80.00High
11/24/2020SVB LeerinkLower TargetMarket Perform$35.00 ➝ $34.00High
11/19/2020Smith Barney CitigroupInitiated CoverageBuy$90.00Low
11/17/2020B. RileyBoost TargetBuy ➝ Positive$68.00 ➝ $98.00Low
11/16/2020Robert W. BairdBoost TargetOutperform$70.00 ➝ $75.00Low
10/12/2020B. RileyBoost Target$57.00 ➝ $68.00Low
10/12/2020HC WainwrightReiterated RatingBuyLow
10/8/2020Piper SandlerBoost Target$80.00 ➝ $90.00High
9/17/2020SVB LeerinkBoost TargetMarket Perform$29.00 ➝ $31.00Low
8/24/2020HC WainwrightReiterated RatingBuyLow
7/29/2020Chardan CapitalReiterated RatingBuy$81.00High
5/12/2020Royal Bank of CanadaInitiated CoverageOutperform$62.00High
5/10/2020B. RileyReiterated RatingBuy$57.00High
5/8/2020Cantor FitzgeraldReiterated RatingBuy$60.00 ➝ $58.00High
5/8/2020OppenheimerUpgradeMarket Perform ➝ Outperform$58.00High
4/15/2020Cantor FitzgeraldUpgradeNeutral ➝ Overweight$55.00 ➝ $60.00High
3/31/2020B. RileyReiterated RatingBuy$57.00High
3/24/2020SVB LeerinkUpgradeUnderperform ➝ Market Perform$29.00Medium
3/17/2020The Goldman Sachs GroupInitiated CoverageNeutral$45.00Medium
3/13/2020B. RileyLower TargetBuy$83.00 ➝ $57.00High
2/7/2020Jefferies Financial GroupBoost Target$77.00 ➝ $80.00Medium
2/6/2020B. RileyReiterated RatingBuy$83.00High
2/6/2020Cantor FitzgeraldBoost TargetNeutral$50.00 ➝ $55.00High
1/24/2020B. RileyReiterated RatingBuy$83.00Low
1/21/2020SVB LeerinkInitiated CoverageUnderperform$32.00High
12/12/2019OppenheimerInitiated CoverageHoldMedium
12/9/2019Piper Sandler CompaniesBoost TargetOverweight$72.00 ➝ $80.00Medium
11/29/2019Chardan CapitalReiterated RatingBuy$45.00 ➝ $81.00Medium
11/27/2019B. RileyReiterated RatingBuy$59.00 ➝ $83.00High
11/26/2019S&P Equity ResearchReiterated RatingBuyMedium
11/26/2019Piper Sandler CompaniesReiterated RatingOverweight$54.00 ➝ $72.00High
11/25/2019Robert W. BairdUpgradeNeutral ➝ Outperform$39.00 ➝ $70.00High
11/19/2019Cantor FitzgeraldReiterated RatingNeutral$24.00 ➝ $50.00Medium
11/13/2019B. RileyBoost TargetBuy$46.00 ➝ $59.00Low
10/24/2019Robert W. BairdDowngradeOutperform ➝ Neutral$39.00High
10/22/2019Chardan CapitalBoost TargetBuy$32.00 ➝ $45.00High
10/21/2019B. RileySet TargetBuy$46.00High
10/20/2019Piper Sandler CompaniesBoost TargetOverweight$50.00 ➝ $54.00Low
10/17/2019Cantor FitzgeraldReiterated RatingNeutralLow
10/2/2019Robert W. BairdInitiated CoverageOutperform$39.00Medium
9/16/2019Piper Sandler CompaniesReiterated RatingOverweight$50.00Medium
8/19/2019B. RileyBoost TargetBuy$32.00 ➝ $46.00High
8/6/2019Piper Sandler CompaniesBoost TargetOverweight$33.00 ➝ $50.00Low
6/27/2019Cantor FitzgeraldDowngradeOverweight ➝ Neutral$24.00High
5/28/2019B. RileyBoost TargetBuy$26.00 ➝ $32.00Low
5/13/2019B. RileyBoost TargetBuy$19.00 ➝ $26.00High
4/16/2019Piper Sandler CompaniesBoost TargetOverweight$25.00 ➝ $33.00Medium
4/12/2019Cantor FitzgeraldSet TargetBuy$24.00Low
2/11/2019Chardan CapitalReiterated RatingBuy$24.50High
12/17/2018Chardan CapitalReiterated RatingBuy$24.50Low
12/11/2018Cantor FitzgeraldSet TargetBuy$24.00High
(Data available from 12/3/2018 forward)

News Sentiment Rating

0.33 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 8 very positive mentions
  • 20 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 13 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 11 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 7 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 12 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
  • 8 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 3 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Arrowhead Pharmaceuticals logo
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Read More

Today's Range

Now: $23.17
Low: $20.67
High: $23.24

50 Day Range

MA: $26.27
Low: $21.20
High: $29.12

52 Week Range

Now: $23.17
Low: $20.67
High: $42.48


4,222,162 shs

Average Volume

1,161,891 shs

Market Capitalization

$2.49 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Arrowhead Pharmaceuticals?

The following equities research analysts have issued research reports on Arrowhead Pharmaceuticals in the last twelve months: Limited, B. Riley, Cantor Fitzgerald, Chardan Capital, Citigroup Inc., HC Wainwright, Morgan Stanley, Piper Sandler, Robert W. Baird, Royal Bank of Canada, Sanford C. Bernstein,, Sumitomo Mitsui Financial Group, Inc., SVB Leerink LLC, SVB Securities, and TD Cowen.
View the latest analyst ratings for ARWR.

What is the current price target for Arrowhead Pharmaceuticals?

12 Wall Street analysts have set twelve-month price targets for Arrowhead Pharmaceuticals in the last year. Their average twelve-month price target is $53.00, suggesting a possible upside of 128.7%. HC Wainwright has the highest price target set, predicting ARWR will reach $90.00 in the next twelve months. Sanford C. Bernstein has the lowest price target set, forecasting a price of $27.00 for Arrowhead Pharmaceuticals in the next year.
View the latest price targets for ARWR.

What is the current consensus analyst rating for Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals currently has 5 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ARWR.

What other companies compete with Arrowhead Pharmaceuticals?

How do I contact Arrowhead Pharmaceuticals' investor relations team?

Arrowhead Pharmaceuticals' physical mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The biotechnology company's listed phone number is (626) 304-3400 and its investor relations email address is [email protected]. The official website for Arrowhead Pharmaceuticals is Learn More about contacing Arrowhead Pharmaceuticals investor relations.